Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
Alzheimer's Disease - From Fundamental Insights to Light at the End of the Translational Tunnel (2014Q8)
New Frontiers in Neurodegenerative Disease Research (2013J8)
Alzheimer's Disease Beyond Abeta (2010A4)

Web Desc
Alzheimer's Disease Organizer(s): David M. Holtzman, Dora M. Kovacs and Cynthia A. Lemere Date: March 24 - 29, 2008 Location: Keystone Resort, Keystone, CO, USA Supported by the Director's Fund Summary of Meeting: Aggregation of the amyloid ß peptide and tau in the brain are key events in Alzheimer’s disease (AD). The understanding of the cell biological processes that lead to Aß formation is advancing rapidly. The cellular release, transport, and clearance of Aß and how Aß influences tau are just beginning to be understood. Studies of pathogenesis and treatment of AD with cellular and animal models are promising. Recent data in humans indicates that fluid and imaging biomarkers for both clinical and pre-clinical AD may be possible. Several pivotal issues that remain are: (1) to develop a full understanding of APP, A beta, and tau biology; (2) to be able to predict AD prior to cognitive decline; and (3) to develop effective methods to prevent and treat AD. The goal of this meeting will be to provide a state of the art update of the genetic, molecular, cell biological, and translational aspects of AD. Integration of current and novel bench and translational science in this area should lead to new ideas and collaborations. Scholarship Deadline: November 26 2007 Discounted Abstract Deadline: November 26 2007 Abstract Deadline: December 26 2007 Discounted Registration Deadline: January 25 2008 We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Merck & Co., Inc. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Alzheimer's Disease

Organizer(s): David M. Holtzman, Dora M. Kovacs and Cynthia A. Lemere

Date: March 24 - 29, 2008
Location: Keystone Resort, Keystone, CO, USA

Supported by the Director's Fund

Summary of Meeting:

Aggregation of the amyloid ß peptide and tau in the brain are key events in Alzheimer’s disease (AD). The understanding of the cell biological processes that lead to Aß formation is advancing rapidly. The cellular release, transport, and clearance of Aß and how Aß influences tau are just beginning to be understood. Studies of pathogenesis and treatment of AD with cellular and animal models are promising. Recent data in humans indicates that fluid and imaging biomarkers for both clinical and pre-clinical AD may be possible. Several pivotal issues that remain are: (1) to develop a full understanding of APP, A beta, and tau biology; (2) to be able to predict AD prior to cognitive decline; and (3) to develop effective methods to prevent and treat AD. The goal of this meeting will be to provide a state of the art update of the genetic, molecular, cell biological, and translational aspects of AD. Integration of current and novel bench and translational science in this area should lead to new ideas and collaborations.

Scholarship Deadline: November 26 2007

Discounted Abstract Deadline: November 26 2007

Abstract Deadline: December 26 2007

Discounted Registration Deadline: January 25 2008

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Merck & Co., Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Monday, March 24 \| 3:00PM - 7:30PM Registration Room: Shavano Peak Foyer
Monday, March 24 \| 6:30PM - 7:30PM Refreshments Room: Shavano Peak Foyer
Monday, March 24 \| 7:30PM - 9:15PM Keynote Session Room: Red Cloud Peak Speaker 1 of 2 Christian Haass, Ludwig-Maximilians University Munich, Germany The Process of Amyloid ß-Peptide generation: Normal and Disease Biology
Monday, March 24 \| 7:30PM - 9:15PM Keynote Session Room: Red Cloud Peak Speaker 2 of 2 Dennis J. Selkoe, Harvard Medical School, USA The End Game in Alzheimer’s Disease: Translating Molecular Mechanisms into Therapeutics
Tuesday, March 25 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Tuesday, March 25 \| 8:00AM - 11:00AM Clinical, Epidemiological, and Genetic Factors Relevant to A D and Related Disorders Room: Red Cloud Peak Speaker 1 of 6 * David M. Holtzman, Washington University, USA
Tuesday, March 25 \| 8:00AM - 11:00AM Clinical, Epidemiological, and Genetic Factors Relevant to A D and Related Disorders Room: Red Cloud Peak Speaker 2 of 6 John Morris, Alzheimer Disease & Associated Disorders, USA Preclinical AD and PreMCI: The Future of Alzheimer Research
Tuesday, March 25 \| 8:00AM - 11:00AM Clinical, Epidemiological, and Genetic Factors Relevant to A D and Related Disorders Room: Red Cloud Peak Speaker 3 of 6 Rudolph E. Tanzi, Massachusetts General Hospital, USA The Continuing Search for Novel Alzheimer's Disease Genes
Tuesday, March 25 \| 8:00AM - 11:00AM Clinical, Epidemiological, and Genetic Factors Relevant to A D and Related Disorders Room: Red Cloud Peak Speaker 4 of 6 Lenore J. Launer, National Institute on Aging, USA Cardiovascular and Non-Genetic Risk Factors for AD
Tuesday, March 25 \| 8:00AM - 11:00AM Clinical, Epidemiological, and Genetic Factors Relevant to A D and Related Disorders Room: Red Cloud Peak Speaker 5 of 6 Elizabeth H. Corder, Duke University, USA Short Talk: Genetic Risk Profiles for Alzheimer’s Disease: Integration of APOE Genotype and Variants that Up-Regulate Inflammation
Tuesday, March 25 \| 8:00AM - 11:00AM Clinical, Epidemiological, and Genetic Factors Relevant to A D and Related Disorders Room: Red Cloud Peak Speaker 6 of 6 Peter J. Hudson, Avipep Pty Ltd, Australia Short Talk: Early Stage Alzheimer’s Disease Diagnosis in a Unique Progressing Cohort by Correlation of Cognition, Neuroimaging and Blood Biomarkers (the AIBL Cluster Study).
Tuesday, March 25 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Tuesday, March 25 \| 11:00AM - 1:00PM Poster Setup Room: Shavano/Torreys
Tuesday, March 25 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano/Torreys
Tuesday, March 25 \| 4:30PM - 5:00PM Coffee Available Room: Shavano Peak Foyer
Tuesday, March 25 \| 5:00PM - 7:00PM APP Processing, Function, and Cell Biology of Neurodegenerat ion Room: Red Cloud Peak Speaker 1 of 5 * Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA
Tuesday, March 25 \| 5:00PM - 7:00PM APP Processing, Function, and Cell Biology of Neurodegenerat ion Room: Red Cloud Peak Speaker 2 of 5 Huaxi Xu, Sanford Burnham Prebys Medical Discovery Institute, USA Pathophysiological Functions of APP: A Potential Function of APP Metabolite AICD in EGFR Signaling and Apoptotic Neuronal Cell Death
Tuesday, March 25 \| 5:00PM - 7:00PM APP Processing, Function, and Cell Biology of Neurodegenerat ion Room: Red Cloud Peak Speaker 3 of 5 Gopal Thinakaran, University of Chicago, USA APP Processing in Lipid Rafts
Tuesday, March 25 \| 5:00PM - 7:00PM APP Processing, Function, and Cell Biology of Neurodegenerat ion Room: Red Cloud Peak Speaker 4 of 5 Hui Zheng, Baylor College of Medicine, USA Role of APP in Synaptic Structure and Function
Tuesday, March 25 \| 5:00PM - 7:00PM APP Processing, Function, and Cell Biology of Neurodegenerat ion Room: Red Cloud Peak Speaker 5 of 5 Patricia V. Burgos, NICHD, National Institutes of Health, USA Short Talk: The AP4 Complex Mediates Sorting of the Amyloid Precursor Protein at the trans-Golgi Network
Tuesday, March 25 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Shavano/Torreys
Tuesday, March 25 \| 7:30PM - 10:00PM Poster Session 1 Room: Shavano/Torreys
Wednesday, March 26 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Wednesday, March 26 \| 8:00AM - 11:15AM Abeta Metabolism, CAA, and Blood-Brain-Barrier Room: Red Cloud Peak Speaker 1 of 6 * Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA
Wednesday, March 26 \| 8:00AM - 11:15AM Abeta Metabolism, CAA, and Blood-Brain-Barrier Room: Red Cloud Peak Speaker 2 of 6 Randall Bateman, Washington University School of Medicine, USA APP/Abeta Synthesis and Clearance in Humans
Wednesday, March 26 \| 8:00AM - 11:15AM Abeta Metabolism, CAA, and Blood-Brain-Barrier Room: Red Cloud Peak Speaker 3 of 6 Mathias Jucker, Hertie-Institute for Clinical Brain Research and DZNE, Germany Mouse Models of Cerebral Abeta and Non-Abeta Amyloid Angiopathies
Wednesday, March 26 \| 8:00AM - 11:15AM Abeta Metabolism, CAA, and Blood-Brain-Barrier Room: Red Cloud Peak Speaker 4 of 6 William E. Van Nostrand, Stony Brook University, USA Tg-SwDI: A Mouse Model to Investigate Cerebral Microvascular Amyloid, Neuroinflammation, and Behavioral Deficits
Wednesday, March 26 \| 8:00AM - 11:15AM Abeta Metabolism, CAA, and Blood-Brain-Barrier Room: Red Cloud Peak Speaker 5 of 6 Donna M. Wilcock, Duke University, USA Short Talk: Neurovascular Unit Changes are Observed in Association with Cerebral Amyloid Angiopathy in Several Mouse Models of Alzheimer’s Disease
Wednesday, March 26 \| 8:00AM - 11:15AM Abeta Metabolism, CAA, and Blood-Brain-Barrier Room: Red Cloud Peak Speaker 6 of 6 Bruce T. Lamb, Indiana University School of Medicine, USA Short Talk: The Role of Inflammation and Beta-Amyloid Oligomers in Triggering Aberrant Neuronal Cell Cycle Events
Wednesday, March 26 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Wednesday, March 26 \| 11:15AM - 1:00PM Poster Setup Room: Shavano/Torreys
Wednesday, March 26 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano/Torreys
Wednesday, March 26 \| 4:30PM - 5:00PM Coffee Available Room: Shavano Peak Foyer
Wednesday, March 26 \| 5:00PM - 7:00PM BACE and Gamma-Secretase Room: Red Cloud Peak Speaker 1 of 5 * David M. Holtzman, Washington University, USA
Wednesday, March 26 \| 5:00PM - 7:00PM BACE and Gamma-Secretase Room: Red Cloud Peak Speaker 2 of 5 Michael S. Wolfe, Brigham and Women's Hospital, Harvard Medical School, USA Biochemistry and Inhibition of Gamma-Secretase and Presenilin-like Proteases
Wednesday, March 26 \| 5:00PM - 7:00PM BACE and Gamma-Secretase Room: Red Cloud Peak Speaker 3 of 5 Takeshi Iwatsubo, University of Tokyo, Japan Structure and Function of the gamma-Secretase Complex
Wednesday, March 26 \| 5:00PM - 7:00PM BACE and Gamma-Secretase Room: Red Cloud Peak Speaker 4 of 5 Robert J. Vassar, Northwestern University Medical School, USA The Role of BACE1 in Alzheimer's Disease
Wednesday, March 26 \| 5:00PM - 7:00PM BACE and Gamma-Secretase Room: Red Cloud Peak Speaker 5 of 5 Doo Yeon Kim, Harvard Medical School, Massachusetts General Hospital, USA Short Talk: BACE1 and gamma-Secretase Regulate Voltage-Gated Sodium Channel Metabolism
Wednesday, March 26 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Shavano/Torreys
Wednesday, March 26 \| 7:30PM - 10:00PM Poster Session 2 Room: Shavano/Torreys
Thursday, March 27 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 1 of 7 * David M. Holtzman, Washington University, USA
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 2 of 7 Kurt R. Brunden, University of Pennsylvania, USA Tau Focused Drug Discovery for Alzheimer’s Disease and Related Tauopathies
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 3 of 7 Fred Van Leuven, Experimental Genetics Group - KU Leuven, Belgium Tau Phosphorylation and Tauopathy in Mouse Models: Amyloid Activates GSK3
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 4 of 7 Karen Hsiao Ashe, University of Minnesota, USA Toward Understanding the Molecular Basis of Tau-induced Memory Loss
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 5 of 7 Erik D. Roberson, University of Alabama at Birmingham, USA Tau and Neuronal Dysfunction
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 6 of 7 Tudor A. Fulga, Vertex Genetic Therapies, USA Short Talk: Actin Cytoskeleton – A Critical Mediator of Neuronal Degeneration in Alzheimer Disease
Thursday, March 27 \| 8:00AM - 11:15AM Tau Function and Dysfunction in AD and Related Disorders Room: Red Cloud Peak Speaker 7 of 7 George S. Bloom, University of Virginia, USA Short Talk: Tau-Dependent Microtubule Loss Induced by Pre-Fibrillar Beta-amyloid
Thursday, March 27 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Thursday, March 27 \| 11:15AM - 1:00PM Poster Setup Room: Shavano/Torreys
Thursday, March 27 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano/Torreys
Thursday, March 27 \| 4:30PM - 5:00PM Coffee Available Room: Shavano Peak Foyer
Thursday, March 27 \| 5:00PM - 7:00PM Biomarkers and Imaging Room: Red Cloud Peak Speaker 1 of 6 * David M. Holtzman, Washington University, USA
Thursday, March 27 \| 5:00PM - 7:00PM Biomarkers and Imaging Room: Red Cloud Peak Speaker 2 of 6 * Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA
Thursday, March 27 \| 5:00PM - 7:00PM Biomarkers and Imaging Room: Red Cloud Peak Speaker 3 of 6 Anne M. Fagan, Washington University School of Medicine, USA CSF and Amyloid Imaging Biomarkers in AD
Thursday, March 27 \| 5:00PM - 7:00PM Biomarkers and Imaging Room: Red Cloud Peak Speaker 4 of 6 Tony Wyss-Coray, Stanford University School of Medicine, USA Plasma protein biomarkers for aging and Alzheimer's disease
Thursday, March 27 \| 5:00PM - 7:00PM Biomarkers and Imaging Room: Red Cloud Peak Speaker 5 of 6 Reisa A. Sperling, Brigham and Women's Hospital, Harvard Medical School, USA Functional and Molecular Imaging in Early AD
Thursday, March 27 \| 5:00PM - 7:00PM Biomarkers and Imaging Room: Red Cloud Peak Speaker 6 of 6 Jessica Koenigsknecht-Talboo, Washington University, USA Short Talk: Dynamic Imaging of Microglia and Abeta Deposition: Evidence of Rapid Responses Following Systemic Anti-Abeta Antibody Administration
Thursday, March 27 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Shavano/Torreys
Thursday, March 27 \| 7:30PM - 10:00PM Poster Session 3 Room: Shavano/Torreys
Friday, March 28 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 1 of 7 * Cynthia A. Lemere, Brigham and Women's Hospital, Harvard Medical School, USA
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 2 of 7 Ronald B. DeMattos, Lilly Research Laboratories, USA Update on Active and Passive Immunotherapy
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 3 of 7 Gerald Koelsch, Astellas Pharma, USA Beta-Secretase Inhibitor CTS-21166 Reduces Plasma Abeta40 in Human Subjects
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 4 of 7 JoAnne McLaurin, University of Toronto, Canada Novel Small Molecule Therapies for AD
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 5 of 7 Takaomi C. Saido, RIKEN Brain Science Institute, Japan N-Terminal Modification of Amyloid-beta Peptide, AbetaX-42, in Alzheimer's Disease and Mouse Models
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 6 of 7 Hans-Ulrich Demuth, Probiodrug AG, Germany Short Talk: Prevention of Abeta3(pE)-42 Formation: A New Causative Treatment Paradigm in AD
Friday, March 28 \| 8:00AM - 11:15AM Therapeutics Room: Red Cloud Peak Speaker 7 of 7 Jonathan Thomas Megerian, Epix Pharmaceuticals, USA Short Talk: Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer’s Disease
Friday, March 28 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Friday, March 28 \| 4:30PM - 5:00PM Coffee Available Room: Shavano Peak Foyer
Friday, March 28 \| 5:00PM - 7:00PM Therapeutics II Room: Red Cloud Peak Speaker 1 of 5 * David M. Holtzman, Washington University, USA
Friday, March 28 \| 5:00PM - 7:00PM Therapeutics II Room: Red Cloud Peak Speaker 2 of 5 Steven L. Wagner, TorreyPines Therapeutics, USA Modulation of the Gamma Secretase Enzyme Complex with Orally Bioavailable Small Molecules
Friday, March 28 \| 5:00PM - 7:00PM Therapeutics II Room: Red Cloud Peak Speaker 3 of 5 Frank M. La Ferla, University of California, Irvine, USA Reversing age-dependent memory impairments in a transgenic model of Alzheimer disease
Friday, March 28 \| 5:00PM - 7:00PM Therapeutics II Room: Red Cloud Peak Speaker 4 of 5 William James Ray, Merck & Co. Inc., USA Targeting Pathways that Lead to the Accumulation of Amyloid
Friday, March 28 \| 5:00PM - 7:00PM Therapeutics II Room: Red Cloud Peak Speaker 5 of 5 Michael Bacher, Philipp-University Marburg, Germany Short Talk: Administration of CNI-1493 inhibits Aß accumulation, amyloid plaque formation, and cognitive deterioration in an animal model of Alzheimer’s disease
Friday, March 28 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Shavano/Torreys
Friday, March 28 \| 8:00PM - 11:00PM Entertainment Room: Shavano/Torreys
Friday, March 28 \| 8:00PM - 11:00PM Cash Bar Room: Shavano/Torreys
Saturday, March 29 \| 10:25AM - 10:25AM Departure *Session Chair.